Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 1,276 of 2,219.
    «« First « Previous 1272  1273  1274  1275  1276  1277  1278  1279  1280  Next» Last»»
    EudraCT Number: 2008-005214-49 Sponsor Protocol Number: 9463-EC-0001 Start Date*: 2009-10-30
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: Randomized, Open label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients
    Medical condition: Fungal infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042941 Systemic fungal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) HU (Completed) ES (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) IT (Completed) SE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000170-70 Sponsor Protocol Number: 20050203 Start Date*: 2006-06-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovori...
    Medical condition: Patients with Previously Untreated Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) EE (Prematurely Ended) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000081-11 Sponsor Protocol Number: BFS-AS-306 Start Date*: 2013-05-28
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent As...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) BE (Completed) IT (Completed) SE (Completed) CZ (Completed) FI (Completed) ES (Completed) PL (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023903-91 Sponsor Protocol Number: PCCE203/10 Start Date*: Information not available in EudraCT
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Medical condition: Patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-002576-18 Sponsor Protocol Number: A4061027 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT
    Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055107 Thyroid cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008192-34 Sponsor Protocol Number: ERD-01-08/EP Start Date*: 2009-08-13
    Sponsor Name:EDMOND PHARMA S.R.L.
    Full Title: THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomized, double-blind, placebo-controlled, parallel group, multicenter...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10029978 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) FR (Completed) DK (Completed) SK (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-003625-46 Sponsor Protocol Number: SCG01SII Start Date*: 2006-03-28
    Sponsor Name:ITALCHIMICI SPA
    Full Title: EFFICACY OF ORAL SODIUM CROMOGLICATE IN THE IRRITABLE BOWEL SYNDROME: A DOUBLE BLIND PLACEBO CONTROLLED MULTICENTRE RANDOMISED STUDY
    Medical condition: IRRITABLE BOWEL SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001949-34 Sponsor Protocol Number: E7389-G000-305 Start Date*: 2006-10-02
    Sponsor Name:Eisai Limited
    Full Title: A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously T...
    Medical condition: Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (Completed) CZ (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000808-41 Sponsor Protocol Number: 1237.11 Start Date*: 2013-08-27
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+o...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) CZ (Completed) BE (Completed) DK (Completed) SE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003094-10 Sponsor Protocol Number: SPI-GCF-12-201 Start Date*: 2014-01-16
    Sponsor Name:Spectrum Pharmaceuticals
    Full Title: Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherap...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy with the Docetaxel + Cyclophosphamide (TC) Regimen
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-004311-31 Sponsor Protocol Number: 0177/DEV Start Date*: 2013-03-20
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets a...
    Medical condition: Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric re...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SK (Completed) ES (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017365-36 Sponsor Protocol Number: GM-IMAB-001-02 Start Date*: 2010-08-11
    Sponsor Name:GANYMED Pharmaceuticals AG
    Full Title: International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esoph...
    Medical condition: advanced adenocarcinoma of the stomach or the lower esophagus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10001173 Adenocarcinoma of esophagus LLT
    14.1 100000004864 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) CZ (Completed) LT (Prematurely Ended) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005067-17 Sponsor Protocol Number: CVT-301-004 Start Date*: 2016-04-01
    Sponsor Name:Civitas Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluct...
    Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003073-26 Sponsor Protocol Number: M13-102 Start Date*: 2013-10-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) ES (Completed) HU (Prematurely Ended) AT (Completed) BE (Completed) DK (Completed) PT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004888-31 Sponsor Protocol Number: OXN3508 Start Date*: 2015-01-26
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as ...
    Medical condition: The intended indication is: Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003021-18 Sponsor Protocol Number: 109MS308 Start Date*: 2015-03-25
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
    Medical condition: Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) IT (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022313-25 Sponsor Protocol Number: CL-503012 Start Date*: 2011-01-17
    Sponsor Name:A.T. Development Switzerland SARL
    Full Title: International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA™ in Preventing Renal Function Decline in Patients With AA Amyloidosis
    Medical condition: Renal Function Decline in Patients With AA Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10002024 Amyloidosis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) GB (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) BG (Completed) PT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004562-22 Sponsor Protocol Number: 109MS416 Start Date*: 2015-06-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with M...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004480-20 Sponsor Protocol Number: GS-US-370-1296 Start Date*: 2015-05-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by ...
    Medical condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000558-40 Sponsor Protocol Number: CCD-06302AA1-01 Start Date*: 2016-03-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A multicenter, randomised, double blind, placebo-controlled, incomplete block, 3-way cross-over study to evaluate the efficacy and safety of 4 doses of glycopyrronium bromide DPI in moderate to sev...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1272  1273  1274  1275  1276  1277  1278  1279  1280  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 14:27:12 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA